MDGL Madrigal Pharmaceuticals (MDGL) Q2 FY26 earnings call
Madrigal Pharmaceuticals reported strong Q2 FY26 results, with Rezdiffra exceeding expectations in patient adds and sales, reinforcing its mega-blockbuster potential. The company is strategically expanding its pipeline with combination therapies to build on Rezdiffra's foundational role in the rapidly growing MASH market. While investing heavily in commercialization and R&D, Madrigal aims to define the future of MASH care, despite current net losses and European reimbursement challenges.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
MDGL operating KPIs by quarter
| KPI | Mar 2026 Q1 FY26 | This call Jun 2026 Q2 FY26 | Change vs prior quarter |
|---|---|---|---|
| Patients Rezdiffra | 42.25K+We ended the first quarter with more than 42,250 active patients on Rezdiffra.Source: earnings call transcript | 49K+That's why we've steadily added patients ending the second quarter with more than 49,000 active patients on Rezdiffra, more than double a year ago.Source: earnings call transcript | — |
Operating figures the company stated on at least two of the calls shown, checked against each call's transcript. Click a figure to read the sentence. A dash means it was not stated that quarter.
Inve summary of the company's earnings call; see how call summaries are prepared. Not investment advice.